Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on August 8, 2022. The filing serves to announce the Company's financial results for the quarter ended June 30, 2022, and to provide updated corporate presentation materials.
Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the source text provided.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text body. It directs readers to the press release (Exhibit 99.1) for the full announcement of results for the quarter ended June 30, 2022.
Guidance, Outlook, and Disclosures
- Regulation FD Disclosure: The Company updated its corporate deck, available on the "Investors & Media" section of its website.
- Forward-Looking Statements: The filing includes standard disclaimers that the information in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release dated August 8, 2022) for specific Q2 2022 financial figures including revenue, net loss, and cash position.
- Verify the updated corporate deck on the Company's investor relations website for current strategic outlook and pipeline updates.
- Confirm the Company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.